Download PDF
Semin Reprod Med 2009; 27(3): 260-274
DOI: 10.1055/s-0029-1216279
© Thieme Medical Publishers

Does Postmenopausal Estrogen Use Confer Neuroprotection?

Tammy L. Loucks1 , Sarah L. Berga2
  • 1Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
  • 2James Robert McCord Professor and Chairman, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
Further Information

Publication History

Publication Date:
28 April 2009 (online)

    Permissions and Reprints

ABSTRACT

Sex steroids modulate brain function at all developmental stages of life. This article focuses on the role of sex steroids after menopause with the intent of addressing the question whether or to what extent sex steroids, particularly estrogenic agents, are neuroprotective for the aging brain of women. The rationale for delving into this complicated topic is that the information and perspective so acquired will aid physicians in counseling surgically and naturally menopausal women about their therapeutic options. Whereas we review and synthesize relevant data from monkey, other animal, cellular, and molecular studies, the emphasis is on human studies and reconciling the disparate evidence. Although the knowledge gaps are considerable, available evidence suggests that extended use of non-oral estradiol is a reasonable course of action if the woman to be treated has a relatively low risk for cardiovascular disease and venous thromboembolism or a high concern about developing dementia. It is important to emphasize that estradiol may negatively impact an already unhealthy individual and yet synergize other health-promoting behaviors such as good nutrition, exercise, and stress reduction in a relatively healthy individual.

KEYWORDS

Menopause - hormones - estradiol - neuroprotection

REFERENCES

  • 1 Morrison J H, Brinton R D, Schmidt P J, Gore A C. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women.  J Neurosci. 2006;  26 10332-10348
    CrossrefPubMedGoogle Scholar
  • 2 Cahill L. His brain, her brain.  Sci Am. 2005;  292 40-47
    PubMedGoogle Scholar
  • 3 Nuñez J L, McCarthy M M. Evidence for an extended duration of GABA-mediated excitation in the developing male versus female hippocampus.  Dev Neurobiol. 2007;  67 1879-1890
    CrossrefPubMedGoogle Scholar
  • 4 Gao S, Hendrie H C, Hall K S, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis.  Arch Gen Psychiatry. 1998;  55 809-815
    CrossrefPubMedGoogle Scholar
  • 5 Plassman B L, Langa K M, Fisher G G et al.. Prevalence of dementia in the united States: the aging, demographics, and memory study.  Neuroepidemiology. 2007;  29 125-132
    CrossrefPubMedGoogle Scholar
  • 6 Feldman H, Levy A R, Hsiung G Y et al.. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results.  Neuroepidemiology. 2003;  22 265-274
    CrossrefPubMedGoogle Scholar
  • 7 Langa K M, Foster N L, Larson E B. Mixed dementia: emerging concepts and therapeutic implications.  JAMA. 2004;  292 2901-2908
    CrossrefPubMedGoogle Scholar
  • 8 Zhu C W, Scarmeas N, Torgan R et al.. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease.  Neurology. 2006;  67 998-1005
    CrossrefPubMedGoogle Scholar
  • 9 National Center for Health Statistics. 2004 Current Resident Tables, Diagnoses, Medications, and Vaccinations: Tables 34 and 38, National Nursing Home Survey (NNHS). June 2008. Available at: http://www.cdc.gov/nchs/about/major/nnhsd/ResidentTables_Estimates.htm#Diagnoses Accessed November 24, 2008
    Google Scholar
  • 10 Ellison J M. A 60-year-old woman with mild memory impairment: review of mild cognitive impairment.  JAMA. 2008;  300 1566-1574
    CrossrefPubMedGoogle Scholar
  • 11 Feldman H H, Jacova D, Robillard A et al.. Diagnosis and treatment of dementia: 2. diagnosis.  Can Med Assoc J. 2008;  178 825-836
    CrossrefPubMedGoogle Scholar
  • 12 Grodstein F, Manson J E, Stampfer M J, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy.  Arch Intern Med. 2008;  168 861-866
    CrossrefPubMedGoogle Scholar
  • 13 Pazol K, Wilson M E, Wallen K. Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques.  J Clin Endocrinol Metab. 2004;  89 2998-3006
    CrossrefPubMedGoogle Scholar
  • 14 Zandi P P, Carlson M C, Plassman B L et al.. Hormone replacement therapy and incidence of Alzheimer disease in older women.  JAMA. 2002;  288 2123-2129
    CrossrefPubMedGoogle Scholar
  • 15 Rocca W A, Bower J H, Maraganore D M et al.. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.  Neurology. 2007;  69 1074-1083
    CrossrefPubMedGoogle Scholar
  • 16 Rocca W A, Grossardt B R, Geda Y E et al.. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy.  Menopause. 2008;  15 1050-1059
    CrossrefPubMedGoogle Scholar
  • 17 Schmidt P J. Mood, depression, and reproductive hormones in the menopausal transition.  Am J Med. 2005;  118(Suppl 12B) 54-58
    PubMedGoogle Scholar
  • 18 Hao J, Janssen W G, Tang Y et al.. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and old female rhesus monkeys.  J Comp Neurol. 2003;  465 540-550
    CrossrefPubMedGoogle Scholar
  • 19 Hao J, Rapp P R, Leffler A E et al.. Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys.  J Neurosci. 2006;  26 2571-2578
    CrossrefPubMedGoogle Scholar
  • 20 Tang Y, Janssen W G, Hao J et al.. Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys.  Cereb Cortex. 2004;  14 215-223
    CrossrefPubMedGoogle Scholar
  • 21 Raichle M E. The brain's dark energy.  Science. 2006;  314 1249-1250
    CrossrefPubMedGoogle Scholar
  • 22 Lobo R A. Menopause and stroke and the effects of hormone therapy.  Climacteric. 2007;  10(S2) 27-31
    PubMedGoogle Scholar
  • 23 Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
    CrossrefPubMedGoogle Scholar
  • 24 Anderson G L, Limacher M, Assaf A R et al.. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291 1701-1712
    CrossrefPubMedGoogle Scholar
  • 25 Seeman T E, McEwen B S, Singer B H, Albert M S, Rowe J W. Increase in urinary cortisol excretion and memory declines: MacArthur studies of successful aging.  J Clin Endocrinol Metab. 1997;  82 2458-2465
    CrossrefPubMedGoogle Scholar
  • 26 Dubal D B, Zhu H, Yu J et al.. Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury.  Proc Natl Acad Sci U S A. 2001;  98 1952-1957
    CrossrefPubMedGoogle Scholar
  • 27 McEwen B S. The molecular and neuroanatomical basis for estrogen effects in the central nervous system.  J Clin Endocrinol Metab. 1999;  84 1790-1797
    CrossrefPubMedGoogle Scholar
  • 28 McEwen B S. Estrogen actions throughout the brain.  Recent Prog Horm Res. 2002;  57 357-384
    CrossrefPubMedGoogle Scholar
  • 29 Wang L, Andersson S, Warner M, Gustafsson J A. Estrogen actions in the brain. Science's STKE.  2002;  Available at: http://www.stke.org/cgl/content/full/sigtrans;2002/138/p.pe29
    PubMedGoogle Scholar
  • 30 Stadberg E, Mattson L A, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population.  Acta Ob Gyn Scand. 1997;  76 442-448
    PubMedGoogle Scholar
  • 31 Hollander L E, Freeman E W, Sammel M D, Berlin J A, Grisso J A, Battistini M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women.  Obstet Gynecol. 2001;  98 391-397
    CrossrefPubMedGoogle Scholar
  • 32 Barrett-Connor E, Young R, Notelovitz M et al.. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.  J Reprod Med. 1999;  44 1012-1020
    PubMedGoogle Scholar
  • 33 Castelo-Branco C, Vicente J J, Figueras F et al.. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern, and sexuality in postmenopausal women.  Maturitas. 2000;  34 161-168
    CrossrefPubMedGoogle Scholar
  • 34 Graham C A, Janssen E, Sanders S A. Effects of fragrance on female sexual arousal and mood across the menstrual cycle.  Psychophysiology. 2000;  37 76-84
    CrossrefPubMedGoogle Scholar
  • 35 Insel T R, Young L, Wang Z. Central oxytocin and reproductive behaviors.  Rev Reprod. 1997;  2 28-37
    PubMedGoogle Scholar
  • 36 Matteo S, Rissman E F. Increased sexual activity during the midcycle portion of the human menstrual cycle.  Horm Behav. 1984;  18 249-255
    CrossrefPubMedGoogle Scholar
  • 37 Pfaff D W. Hormones, genes, and behavior.  Proc Natl Acad Sci U S A. 1997;  94 14213-14216
    CrossrefPubMedGoogle Scholar
  • 38 Savic I, Berglund H, Gulyas B, Roland P. Smelling of odorous sex hormone-like compounds causes sex-differentiated hypothalamic activations in humans.  Neuron. 2001;  31 661-668
    CrossrefPubMedGoogle Scholar
  • 39 Warner P, Bancroft J. Mood, sexuality, oral contraceptives, and the menstrual cycle.  J Psychosom Res. 1988;  32 417-427
    CrossrefPubMedGoogle Scholar
  • 40 Finkelstein J W, Susman E J, Chinchilli V M et al.. Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents.  J Clin Endocrinol Metab. 1997;  82 2433-2438
    CrossrefPubMedGoogle Scholar
  • 41 Finkelstein J W, Susman E J, Chinchilli V M et al.. Effects of estrogen or testosterone on self-reported sexual responses and behaviors in hypogonadal adolescents.  J Clin Endocrinol Metab. 1998;  83 2281-2285
    CrossrefPubMedGoogle Scholar
  • 42 Birge S J. HRT and cognitive function: what are we to believe?.  Menopause. 2002;  9 221-223
    CrossrefPubMedGoogle Scholar
  • 43 Duka T, Tasker R, McGowan J F. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females.  Psychopharmacology (Berl). 2000;  149 129-139
    CrossrefPubMedGoogle Scholar
  • 44 Hogervost E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.  Neuroscience. 2000;  101 485-512
    CrossrefPubMedGoogle Scholar
  • 45 LeBlanc E S, Janowsky J, Chan B KS, Nelson H D. Hormone replacement therapy and cognition.  JAMA. 2001;  285 1489-1499
    CrossrefPubMedGoogle Scholar
  • 46 Resnick S M, Maki P M. Effects of hormone replacement therapy on cognitive and brain aging.  Ann N Y Acad Sci. 2001;  949 203-214
    PubMedGoogle Scholar
  • 47 Wolf O T, Kudielka B M, Hellhammer D H, Torber S, McEwen B S, Kirschbaum C. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels.  Psychoneuroendocrinology. 1999;  24 727-741
    CrossrefPubMedGoogle Scholar
  • 48 Irwin R W, Yao J, Hamilton R T, Cadenas E, Brinton R D, Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria.  Endocrinology. 2008;  149 3167-3175
    CrossrefPubMedGoogle Scholar
  • 49 Smith Y R, Zubieta J K. Neuroimaging of aging and estrogen effects on central nervous system physiology.  Fertil Steril. 2001;  76 651-659
    CrossrefPubMedGoogle Scholar
  • 50 Gibbs R B. Basal forebrain cholinergic neurons are necessary for estrogen to enhance acquisition of a delayed matching-to-position T-maze task.  Horm Behav. 2002;  42 245-257
    CrossrefPubMedGoogle Scholar
  • 51 Moses E L, Drevets W C, Smith G et al.. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study.  Biol Psychiatry. 2000;  48 854-860
    CrossrefPubMedGoogle Scholar
  • 52 Maki P M, Resnick S M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition.  Neurobiol Aging. 2000;  21 373-383
    CrossrefPubMedGoogle Scholar
  • 53 Kugaya A, Epperson C N, Zoghbi S et al.. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women.  Am J Psychiatry. 2003;  160 1522-1524
    CrossrefPubMedGoogle Scholar
  • 54 Rasgon N L, Silverman D, Siddarth P et al.. Estrogen use and brain metabolic change in postmenopausal women.  Neurobiol Aging. 2005;  26 229-235
    CrossrefPubMedGoogle Scholar
  • 55 Smith Y R, Minoshima S, Kuhl D E, Zubieta J K. Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women.  J Clin Endocrinol Metab. 2001;  86 679-684
    CrossrefPubMedGoogle Scholar
  • 56 Moses-Kolko E L, Berga S L, Greer P J, Smith G, Cidis Meltzer C, Drevets W C. Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women.  Fertil Steril. 2003;  80 554-559
    CrossrefPubMedGoogle Scholar
  • 57 Shaywitz S E, Naftolin F, Zelterman D et al.. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen.  Menopause. 2003;  10 420-426
    CrossrefPubMedGoogle Scholar
  • 58 Joffe H, Hall J E, Gruber S et al.. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.  Menopause. 2006;  13 411-422
    CrossrefPubMedGoogle Scholar
  • 59 Persad C C, Zubieta J K, Love T, Wang H, Tkaczyk A, Smith Y R. Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy.  Fertil Steril. 2008 August;  8 , (Epub ahead of print)
    PubMedGoogle Scholar
  • 60 Helwick C. Estrogen may be neuroprotective after all. Medscape Medical News, June 18, 2009. Study authors: Geist C, Silverman D. http://Available at: www.medscape.com/viewarticle/576259 Accessed March 31, 2009
    Google Scholar
  • 61 Bender C M, Sereika S M, Berga S L et al.. Cognitive impairment associated with adjuvant therapy in breast cancer.  Psychooncology. 2006;  15 422-430
    CrossrefPubMedGoogle Scholar
  • 62 Bender C M, Sereika S M, Brufsky A M et al.. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.  Menopause. 2007;  14 995-998
    CrossrefPubMedGoogle Scholar
  • 63 Jenkins V A, Ambroisine L M, Atkins L, Cuzick J, Howell A, Fallowfield L J. The effects of anastrozole on cognitive performance in postmenopausal women participating in a randomized double blind chemoprevention trial (IBIS II).  Lancet Oncol. 2008;  9 753-761
    PubMedGoogle Scholar
  • 64 Berga S L. Anastrozole: brain draining or sparing?.  Lancet Oncol. 2008;  9 913-914
    CrossrefPubMedGoogle Scholar
  • 65 Mook D, Felger J, Graves F, Wallen K, Wilson M E. Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques.  Psychoneuroendocrinology. 2005;  30 273-283
    CrossrefPubMedGoogle Scholar
  • 66 Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents.  Women Health. 2000;  31 71-85
    PubMedGoogle Scholar
  • 67 Wilson M E, Mook D, Graves F C, Gleger J, Bielsky I R, Wallen K. Tamoxifen is an estrogen antagonist on gonadotropin secretion and responsiveness of the hypothalamic-pituitary-adrenal axis in female monkeys.  Endocrine. 2003;  22 305-315
    CrossrefPubMedGoogle Scholar
  • 68 Lacreuse A, Wilson M E, Herndon J G. Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys.  Neurobiol Aging. 2002;  23 589-600
    CrossrefPubMedGoogle Scholar
  • 69 Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.  Cochrane Database Syst Rev. 2008;  (1) CD003122
    PubMedGoogle Scholar
  • 70 Rocca W A, Grossardt B R, de Andrade M, Malkasian G D, Melton III L J. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study.  Lancet Oncol. 2006;  7 821-828
    CrossrefPubMedGoogle Scholar
  • 71 Rocca W A, Bower J H, Maraganore D M et al.. Increased risk of parkinsonism in women who underwent oophorectomy before menopause.  Neurology. 2008;  70 200-209
    CrossrefPubMedGoogle Scholar
  • 72 Benedetti M D, Maraganore D M, Bower J H et al.. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study.  Mov Disord. 2001;  16 830-837
    CrossrefPubMedGoogle Scholar
  • 73 Marchbanks P A, McDonald J A, Wilson H G et al.. Oral contraceptives and the risk of breast cancer.  N Engl J Med. 2002;  346 2025-2032
    CrossrefPubMedGoogle Scholar
  • 74 Shumaker S A, Legault C, Rapp S R et al.. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.  JAMA. 2003;  289 2651-2662
    CrossrefPubMedGoogle Scholar
  • 75 Shumaker S A, Legault C, Kuller L et al.. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.  JAMA. 2004;  291 2947-2958
    CrossrefPubMedGoogle Scholar
  • 76 Neiss M B, Carello P E, Samuels M H, Janowsky J S. LeBlancES . Hot flashes and estrogen therapy do not influence cognition in early menopausal women.  Menopause. 2007;  14 191-200
    CrossrefPubMedGoogle Scholar
  • 77 Hlatky M A, Boothroyd D, Vittinghoff E, Sharp P, Whooley M A. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy.  JAMA. 2002;  287 591-597
    CrossrefPubMedGoogle Scholar
  • 78 Berga S L. Does estrogen use support cognition in postmenopausal women?.  Menopause. 2007;  14 163-165
    PubMedGoogle Scholar
  • 79 Whooley M A, Grady D, Cauley J A. Postmenopausal estrogen therapy and depressive symptoms in older women.  J Gen Intern Med. 2000;  15 535-541
    CrossrefPubMedGoogle Scholar
  • 80 Yaffe K, Liu L Y, Grady D, Cauley J, Kramer J, Cummings S R. Cognitive decline in relation to non-protein-bound oestradiol concentrations.  Lancet. 2000;  356 708-712
    CrossrefPubMedGoogle Scholar
  • 81 Canonico M, Oger E, Plu-Bureau G et al.. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.  Circulation. 2007;  115 840-845
    CrossrefPubMedGoogle Scholar
  • 82 Post M S, Christella M, Thomassen L G et al.. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.  Arterioscler Thromb Vasc Biol. 2003;  23 1116-1121
    CrossrefPubMedGoogle Scholar
  • 83 Scarabin P Y, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362 428-432
    CrossrefPubMedGoogle Scholar
  • 84 Straczek C, Oger E, Yon de Jonage-Canonico M B et al.. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of administration.  Circulation. 2005;  112 3495-3500 S
    CrossrefPubMedGoogle Scholar
  • 85 Gleason C E, Schmitz T W, Hess T et al.. Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation.  Neurology. 2006;  67 2039-2041
    CrossrefPubMedGoogle Scholar
  • 86 Mulnard R A, Cotman C W, Kawas C et al.. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized, clinical trial. Alzheimer's Disease Cooperative Study.  JAMA. 2000;  283 1007-1015
    CrossrefPubMedGoogle Scholar
  • 87 MacLennan A H, Henderson V W, Paine B J et al.. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study.  Menopause. 2006;  13 28-36
    CrossrefPubMedGoogle Scholar
  • 88 Weuve J, Kang J H, Manson J E, Breteler M M, Ware J H, Grodstein F. Physical activity, including walking, and cognitive function in older women.  JAMA. 2004;  292 1454-1461
    CrossrefPubMedGoogle Scholar
  • 89 Lautenschlager N T, Cox K L, Flicker L et al.. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.  JAMA. 2008;  300 1027-1037
    CrossrefPubMedGoogle Scholar

Sarah L BergaM.D. 

1639 Pierce Drive, Suite 4208-WMB

Atlanta, GA 30322

Email: sberga@emory.edu

      >